Bio News
Cytokinetics said 10 patients in the Myqorzo treatment group experienced a specific type of heart failure in a heart failure trial, compared with three in the placebo group. Stifel said the efficacy data were robust but analyzed that debate over the drug’s safety in patients with nonobstructive disease is likely to continue.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
